loading page

COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates
  • J. Ulm,
  • Stanley Nelson
J. Ulm
UCLA
Author Profile
Stanley Nelson
UCLA
Author Profile

Abstract

Repurposing of existing antiviral drugs, immunological modulators, and supportive therapies represents a promising path toward rapidly developing new control strategies to mitigate the devastating public health consequences of the COVID-19 pandemic. A comprehensive text-mining and manual curation approach was used to comb and summarize the most pertinent information from existing clinical trials. Drugs with previous efficacy against related betacoronaviruses like SARS and MERS were also systematically evaluated as potentially promising candidates for drug repositioning.

Peer review status:ACCEPTED

24 Apr 2020Submitted to Transboundary and Emerging Diseases
27 Apr 2020Submission Checks Completed
27 Apr 2020Assigned to Editor
28 Apr 2020Reviewer(s) Assigned
13 Jun 2020Review(s) Completed, Editorial Evaluation Pending
14 Jun 2020Editorial Decision: Revise Minor
18 Jun 20201st Revision Received
20 Jun 2020Submission Checks Completed
20 Jun 2020Assigned to Editor
25 Jun 2020Review(s) Completed, Editorial Evaluation Pending
25 Jun 2020Editorial Decision: Accept